Showing 2041-2050 of 2192 results for "".
- Rare Genetic Mutations Linked to Parkinson Disease Identified in Pilot Studyhttps://practicalneurology.com/news/rare-genetic-mutations-linked-to-parkinson-disease-identified-in-pilot-study/2469313/In the PD GENEration: Mapping the Future of Parkinson's Disease pilot study (NCT04057794), approximately 17% of all participants tested positive for genetic mutations linked to Parkinson
- FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndromehttps://practicalneurology.com/news/fda-approves-fenfluramine-for-treatment-of-seizures-associated-with-dravet-syndrome/2469308/The Food and Drug Administration (FDA) has approved fenfluramine (Fintepla; Zogenix, Emeryville, CA), oral solution for treatment of seizures associated with Dravet syndrome (DS) in individuals age 2 years or more. Fenfluramine will be launched through a restricted distribution program, called th
- Phase 2 Clinical Trial for Stem-Cell Treatment of Alzheimer Disease Plannedhttps://practicalneurology.com/news/phase-2-clinical-trial-for-stem-cell-treatment-of-alzheimer-disease-planned/2469305/A phase 2 clinical trial to evaluate the safety and efficacy of treatment in individuals with prodromal to mild Alzheimer disease (AD) is planned for the autologous neurotrophic factor-secreting mesenchymal stem cell (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY). The program is be
- Children Treated With Nusinersen Continue Meeting Developmental Motor Milestoneshttps://practicalneurology.com/news/children-treated-with-nusinersen-continue-meeting-developmental-motor-milestones/2469290/When used as prolonged treatment for children with spinal muscular atrophy (SMA), nusinersen (Spinraza; Biogen Inc., Cambridge, MA) results in progressive improvements in motor function. The early and continuous treatment with nusinersen for 4.8 years enabled unprecedented survival in participant
- Investigation of Foralumab for Alzheimer Disease Treatment Will Continue to Phase 2https://practicalneurology.com/news/investigation-of-foralumab-for-alzheimer-disease-treatment-will-continue-to-phase-2/2469286/Nasally administered foralumab (Tiziana Life Sciences, New York, NY) has showed delays in disease processes underlying the progression of Alzheimer disease (AD) in animal models . Based on those results, the investigation of foralumab for AD will continue to phase 2 clinical trials. Foralum
- Phase 2 Clinical Trial Initiated for Bryostatin Treatment of Alzheimer Diseasehttps://practicalneurology.com/news/phase-2-clinical-trial-initiated-for-bryostatin-treatment-of-alzheimer-disease/2469281/Researchers will evaluate the long-term therapeutic effect of bryostatin-1 (Neurotrope, New York, NY) for Alzheimer disease (AD) in a new phase 2 clinical study (NCT02221947). An estimated 10
- Blood Test May Help Predict Disease Progression in Individuals with Multiple Sclerosishttps://practicalneurology.com/news/blood-test-may-help-predict-disease-progression-in-individuals-with-multiple-sclerosis/2469268/A study published in Neurology shows that a blood test may help predict worsening of multiple sclerosis (MS) likely to occur within the next year. The test can detect a neurofilament light (NfL) cha
- New Social Networking Platform for the Multiple Sclerosis Communityhttps://practicalneurology.com/news/new-social-networking-platform-for-the-multiple-sclerosis-community/2469254/A new free anonymous AI-powered social networking and navigation platform, BelongMS (Belong.Life, New York, NY), has been launched for individuals with multiple sclerosis (MS), caregivers, and healthcare professionals. The app can be downloaded for Android and iOS. The new app follows t
- Higher Rates of COVID-19 Infection and Death for People With Parkinson Diseasehttps://practicalneurology.com/news/higher-rates-of-covid-19-infection-and-death-for-people-with-parkinson-disease/2469246/A paper accepted for publication in Movement Disorders suggests that people with Parkinson disease (PD) with longer disease duration (mean 12.7 years) may be more susceptible to infection with the SARS-CoV2 virus (COVID-19). Individual
- Risdiplam Resulted in Sitting Without Support for 5 Seconds by Month 12 for Infants with SMAhttps://practicalneurology.com/news/risdiplam-resulted-in-sitting-without-support-for-5-seconds-by-month-12-for-infants-with-sma/2469243/At the 1-year point of the Firefish part 2 (NCT02913482), a pivotal global study evaluating risdiplam (Genentech, San Francisco, CA), 29% (12/41; P<.0001) of infants with spinal muscular a